ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Auxillium, makers of Testim, Sales Decline After Negative Testosterone Press
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 7666" data-attributes="member: 3"><p>[ATTACH]750[/ATTACH]</p><p></p><p></p><p></p><p>In the first quarter of 2014, the Company expects to record worldwide Testim revenues of approximately $11 to 13 million, compared to $45.5 million in the first quarter of 2013; full-year Testim sales for 2014 are now expected to be less than $85 million. The Company is continuing to finalize the close for the first quarter and will announce its total definitive net revenue, including definitive net revenue for Testim, on its earnings call planned for May 5, 2014.</p><p></p><p>The Company believes that the unexpected decline in Testim revenues in the first quarter of 2014, and the anticipated impact on expected 2014 Testim total revenues, was, and could continue to be, respectively, influenced by several factors, including, but not necessarily limited to:</p><p></p><p> -- A shrinking testosterone replacement therapy (TRT) gel market and lower </p><p> Testim market share; </p><p> </p><p> -- <strong>Downward pressure on prescriptions in the TRT gel market, due to (i) </strong></p><p><strong> recent communications by the U.S. Food and Drug Administration regarding </strong></p><p><strong> its plans to study the safety of TRT products; (ii) recent medical </strong></p><p><strong> journal publications suggesting potential health risks associated with </strong></p><p><strong> TRT products; (iii) extensive multimedia advertisement by plaintiffs' </strong></p><p><strong> attorneys regarding litigation against companies marketing TRT products; </strong></p><p><strong> and (iv) the commencement of such litigation against companies marketing </strong></p><p><strong> TRT products, including Auxilium, which the Company believes could result </strong></p><p><strong> in total prescription volume for the TRT gel market for full year 2014 </strong></p><p><strong> being as much as 25% below 2013; </strong></p><p> </p><p> -- A greater-than-expected destocking of Testim inventory in the wholesale </p><p> and retail channels; </p><p> </p><p> -- A greater-than-expected decrease in the Company's highest-margin </p><p> non-contracted prescriptions, resulting in a higher-than-expected average </p><p> rebate percentage applying to Testim sales as a whole; and </p><p> </p><p> -- Specifically for the first quarter of 2014, the Company being required to </p><p> accrue a liability for the higher-than-expected rebates and allowances on </p><p> all Testim units estimated to be in the wholesale and retail distribution </p><p> channels.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 7666, member: 3"] [ATTACH=CONFIG]750[/ATTACH] In the first quarter of 2014, the Company expects to record worldwide Testim revenues of approximately $11 to 13 million, compared to $45.5 million in the first quarter of 2013; full-year Testim sales for 2014 are now expected to be less than $85 million. The Company is continuing to finalize the close for the first quarter and will announce its total definitive net revenue, including definitive net revenue for Testim, on its earnings call planned for May 5, 2014. The Company believes that the unexpected decline in Testim revenues in the first quarter of 2014, and the anticipated impact on expected 2014 Testim total revenues, was, and could continue to be, respectively, influenced by several factors, including, but not necessarily limited to: -- A shrinking testosterone replacement therapy (TRT) gel market and lower Testim market share; -- [B]Downward pressure on prescriptions in the TRT gel market, due to (i) recent communications by the U.S. Food and Drug Administration regarding its plans to study the safety of TRT products; (ii) recent medical journal publications suggesting potential health risks associated with TRT products; (iii) extensive multimedia advertisement by plaintiffs' attorneys regarding litigation against companies marketing TRT products; and (iv) the commencement of such litigation against companies marketing TRT products, including Auxilium, which the Company believes could result in total prescription volume for the TRT gel market for full year 2014 being as much as 25% below 2013; [/B] -- A greater-than-expected destocking of Testim inventory in the wholesale and retail channels; -- A greater-than-expected decrease in the Company's highest-margin non-contracted prescriptions, resulting in a higher-than-expected average rebate percentage applying to Testim sales as a whole; and -- Specifically for the first quarter of 2014, the Company being required to accrue a liability for the higher-than-expected rebates and allowances on all Testim units estimated to be in the wholesale and retail distribution channels. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Auxillium, makers of Testim, Sales Decline After Negative Testosterone Press
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top